BEAMBeam Therapeutics Inc.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6,000+0.0% YoY

Gross Profit

-$46M-759516.7% margin

Operating Income

-$59M-982900.0% margin

Net Income

-$76M-1270883.3% margin

EPS (Diluted)

$-1.23

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$49M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$893M

Total Liabilities

$345M

Stockholders' Equity

$549M

Cash & Equivalents

$212M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6,000	$6,000	+0.0%
Gross Profit	-$46M	-$19M	-135.5%
Operating Income	-$59M	-$26M	-124.4%
Net Income	-$76M	-$34M	-122.8%

BEAM Q2 2021 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena